MedPath

Clinical trial for the efficacy and safety of paste type acellular dermal matrix in chronic wound healing.

Not Applicable
Recruiting
Conditions
Diseases of the skin and subcutaneous tissue
Registration Number
KCT0003027
Lead Sponsor
Hanyang University Seoul Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
90
Inclusion Criteria

adults over 19 years
- Dermal defect from skin defect in Full-thickness skin to bone exposure level after debriment in wound area
- chronic wounds that have not been healed despite adequate treatment for more than 3 weeks after wounds
- At the time of the study, patients with a wound size of 4 cm2 or more

Exclusion Criteria

- Patients with superficial or partial thickness skin defect
- Patient with osteomyelitis
- Undermining wound, tunneling wound which can not measure the exact depth (can participate if open wound due to debriment)
- Patients who exceeded 12% of HbA1C within 3 months before participating in the study
- Patients with a serum creatinine concentration of 3.0 mg/dL or more within 30 days before participating in the study
- Patients who have applied other medical devices and growth factors for wound healing within 30 days before participating in the study
- Patients with wound infections (available after infection treatment)

Study & Design

Study Type
Observational Study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
At the start of treatment by each group Wound size reduction rate(%) after 12 weeks compared to wound size
Secondary Outcome Measures
NameTimeMethod
wound closure rate;The period to complete wound closure;The changes in the level of tissue exposed (divided into partial thickness skin, full thickness skin, subQ, deep fascia, muscle, tendon, bone);adverse events
© Copyright 2025. All Rights Reserved by MedPath